Steve is a Director within North Highland's Global Life Sciences vertical, co-leading its Cell & Gene therapy practice. He is a seasoned supply chain and technical operations leader, with 15 years of experience spanning leadership roles within Celgene (a Bristol Myers Squibb company), Johnson & Johnson, and in biopharma management consulting. He combines deep technical, scientific, and business acumen to accelerate R&D productivity and transform supply chains. Steve’s present focus is on advancing the 'art of the possible' to deliver life-changing therapies faster, more affordably, and at scale--unlocking the promise of cell & gene therapies.
Gene-modified cell therapies remain trapped in a high-cost, low-throughput paradigm, with ~40,000 patients treated to date versus the million-plus we must reach in the next decade. Solving the challenge demands new thinking. By fusing advanced analytics and agentic AI with proven playbooks from retail/CPG, automotive, agriculture, and fashion industries, we can compress vein-to-vein time, reduce costs, and enable quality at scale.
This session distils those insights into a five-step roadmap—people, process, data, tech, culture—to develop a scalable, adaptive value chain ready for the next million patients.
Gene-modified cell therapies remain trapped in a high-cost, low-throughput paradigm, with ~40,000 patients treated to date versus the million-plus we must reach in the next decade. Solving the challenge demands new thinking. By fusing advanced analytics and agentic AI with proven playbooks from retail/CPG, automotive, agriculture, and fashion industries, we can compress vein-to-vein time, reduce costs, and enable quality at scale.
This session distils those insights into a five-step roadmap—people, process, data, tech, culture—to develop a scalable, adaptive value chain ready for the next million patients.